These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8725212)

  • 1. More information on vancomycin clearance by new hemodialysis membranes.
    Mueller BA; Scott MK; Clark WR
    Am J Health Syst Pharm; 1996 Jun; 53(11):1339-40, 1348. PubMed ID: 8725212
    [No Abstract]   [Full Text] [Related]  

  • 2. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
    Smith PF; Petros WP; Soucie MP; Copeland KR
    Ther Drug Monit; 1998 Apr; 20(2):231-5. PubMed ID: 9558140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Falsely elevated serum vancomycin concentrations in hemodialysis patients.
    Follin SL; Mueller BA; Scott MK; Carfagna MA; Kraus MA
    Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure.
    Saunders NJ; Want SV; Adams DJ
    J Antimicrob Chemother; 1995 Aug; 36(2):411-5. PubMed ID: 8522471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique.
    Peckman HJ; Dupuis RE; Sawyer WT; Brouwer KL; Cross RE
    Ther Drug Monit; 1996 Dec; 18(6):647-53. PubMed ID: 8946660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies.
    Azzazy HM; Chou PP; Tsushima JH; Troxil S; Gordon M; Avers RJ; Chiappetta E; Duh SH; Christenson RH
    Ther Drug Monit; 1998 Apr; 20(2):202-8. PubMed ID: 9558135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.
    Somerville AL; Wright DH; Rotschafer JC
    Pharmacotherapy; 1999 Jun; 19(6):702-7. PubMed ID: 10391415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay.
    Morishige H; Shuto H; Ieiri I; Otsubo K; Oishi R
    Ther Drug Monit; 1996 Feb; 18(1):80-5. PubMed ID: 8848826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of vancomycin serum concentrations in patients with renal failure.
    Perino LM; Mueller BA
    Ann Pharmacother; 1993; 27(7-8):892-3. PubMed ID: 8364273
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical estimation of vancomycin measurement method on hemodialysis patient.
    Tanaka M; Orii T; Gomi T; Kobayashi H; Kanke M; Hirono S
    Yakugaku Zasshi; 2002 Apr; 122(4):269-75. PubMed ID: 11968839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a quantitative vancomycin immunoassay for the Abbott AxSYM analyzer.
    Adamczyk M; Brate EM; Chiappetta EG; Ginsburg S; Hoffman E; Klein C; Perkowitz MM; Rege SD; Chou PP; Costantino AG
    Ther Drug Monit; 1998 Apr; 20(2):191-201. PubMed ID: 9558134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference with vancomycin fluorescence polarisation immunoassay in a nonuraemic patient.
    Bowhay S; Timms P
    Ther Drug Monit; 1997 Feb; 19(1):117-9. PubMed ID: 9029761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure.
    Najjar TA; al-Dhuwailie AA; Tekle A
    J Chromatogr B Biomed Appl; 1995 Oct; 672(2):295-9. PubMed ID: 8581137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
    Kingery JR; Sowinski KM; Kraus MA; Klaunig JE; Mueller BA
    Pharmacotherapy; 2000 Jun; 20(6):653-6. PubMed ID: 10853620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressant drugs--the role of therapeutic drug monitoring.
    Johnston A; Holt DW
    Br J Clin Pharmacol; 2001; 52 Suppl 1(Suppl 1):61S-73S. PubMed ID: 11564054
    [No Abstract]   [Full Text] [Related]  

  • 16. An update on vancomycin dosing and monitoring practices in hemodialysis patients.
    Zhang M; Dresser L; Battistella M
    CANNT J; 2013; 23(4):25-7; quiz 28-9. PubMed ID: 24660521
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of falsely elevated vancomycin concentrations in end-stage renal disease.
    Kim JS; Perkins RJ; Briceland LL; Tobin EH
    Ann Pharmacother; 1999 Jan; 33(1):116-8. PubMed ID: 9972400
    [No Abstract]   [Full Text] [Related]  

  • 18. An improved micromethod for vancomycin determination by high-performance liquid chromatography.
    Li L; Miles MV; Hall W; Carson SW
    Ther Drug Monit; 1995 Aug; 17(4):366-70. PubMed ID: 7482691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New liquid chromatography-tandem mass spectrometry method for routine TDM of vancomycin in patients with both normal and impaired renal functions and comparison with results of polarization fluoroimmunoassay in light of varying creatinine concentrations.
    Brozmanová H; Kacířová I; Uřinovská R; Šištík P; Grundmann M
    Clin Chim Acta; 2017 Jun; 469():136-143. PubMed ID: 28392327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin monitoring in term newborns: comparison of peak and trough serum concentrations determined by high performance liquid chromatography and fluorescence polarization immunoassay.
    Feferbaum R; Kobol Machado JK; de Albuquerque Diniz EM; Okay TS; Santos SR; Ceccon ME; Krebs VL; de Araújo MC; Costa Vaz A
    Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(5):149-52. PubMed ID: 11781595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.